



## Overview

Expanesthetics is the global leader in the search for new, improved inhaled general anesthetics. We're using our screening technology to transform this multi-billion dollar global market by identifying molecules that may have benefits over existing anesthetics with fewer unwanted effects. Anesthesia providers continue to affirm the need for improvements in current anesthetic agents as demonstrated by our market research. In addition, market conditions such as changes in patient demographics, increased focus on improved surgical outcomes, and "pay-for-performance" have created ideal conditions for the development of new, improved anesthetic agents. To our knowledge, no other company is making investments in R&D to develop the next generation of inhaled anesthetic agents.

Because the molecular mechanism of the inhaled anesthetics has been unknown, an efficient screening process for identifying new candidates has not been possible. With sevoflurane and desflurane first becoming commercially available in the 1980s and early 1990s, there have been no new molecular entities for inhaled anesthesia in over 20 years. And even these agents were discovered about half a century ago. Expanesthetics is built on a major discovery regarding the molecular mechanism of the inhaled anesthetics that has given us a roadmap and an efficient screening process for identifying new inhaled anesthetic candidates.

As a potential added benefit of developing new anesthetic drugs to disruptively transform the anesthesia market, Expanesthetics is energized by the idea that these potential new drugs could also help alleviate suffering and promote prosperity around the world. If these new and better anesthetic drugs lower the cost to safely deliver anesthesia care, it could result in a long-term increase in surgical access for [the estimated 5 billion people around the world](#) who lack access to safe surgical and anesthesia care. That could in turn curb [the \\$12.3 trillion productivity loss](#) that the world is projected to suffer by 2030 due to lack of access to surgical and anesthesia care.

## Speaker Profile

### Mark Holman, Chairman

Mark Holman is a veteran generalist with experience and leadership success in the fields of communication, consulting, education, entrepreneurship, media, medicine, nonprofits, politics, and more.

Mark graduated from the University of California with an honors degree in Rhetoric & Communication, and later studied Plant Biology at UC Davis with a research emphasis in plant-derived anti-neoplastic pharmaceuticals. Both before and during his post-baccalaureate studies he became a published medical research associate in the fields of pediatric orthopedics and pediatric hematology/oncology.



He has guided a wide variety of businesses to success in an executive capacity, including SunTherm Energy, a solar thermal energy company for which he chaired the board of directors until the business was sold in an equity transaction to its leading Silicon Valley competitor.



Mark is now the founder, Chairman and CEO of Expanesthetics, Inc., where he has led the company through millions in fundraising, rebuilt the global infrastructure for inhaled anesthetic development, and fostered partnerships with leading organizations in the biopharmaceuticals industry. He also serves as Chairman of the Board of the Patrick Henry Memorial Foundation - a multi-million dollar foundation that runs the official US Memorial to Patrick Henry. He recently retired from Board of Advisors for Lamplighter Financial, a firm providing CFO services to private equity funds, upon its acquisition by NY-based Leverpoint Financial.